Physician profile
Julia M Hypes
NPI 1598431942
$4,881.46
in general payments reported to CMS, 2019-2025
21 companies · $742 in 2025
The $742 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,301 · 2022: $1,989 · 2023: $128 · 2024: $721 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $921.71 | 2021-2025 | Enbrel, Otezla, Enbrel |
| Janssen Biotech, INC. | $824.89 | 2021-2025 | Tremfya |
| Abbvie INC. | $472.84 | 2021-2025 | |
| Ucb, INC. | $468.18 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $385.84 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $345.61 | 2021-2022 | |
| Lilly USA, LLC | $299.74 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Novartis Pharmaceuticals Corporation | $196.86 | 2021-2025 | |
| Horizon Therapeutics Plc | $129.88 | 2022 | |
| Pfizer INC. | $128.95 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $114.72 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $114.24 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $98.32 | 2021-2022 | |
| Genentech USA, INC. | $93.52 | 2023-2025 | Actemra |
| Glaxosmithkline, LLC. | $76.89 | 2021-2025 | Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $66.36 | 2022 | |
| Merz North America, INC. | $50.52 | 2022 | |
| Fresenius Kabi USA, LLC | $47.45 | 2023-2025 | Idacio |
| Actelion Pharmaceuticals US, INC. | $20.64 | 2024 | Opsumit |
| Ibsa Pharma INC. | $17.64 | 2021 | |
| Organon LLC | $6.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Hypes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.